Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study

Key Points

• Improved efficacy observed with the combination of anti-LAG-3 and sintilimab in patients.
• Significant findings included a notable progression-free survival of 10.5 months in treatment groups.
• Observational analysis across multiple centers assessing phase II clinical trial data.
• Findings highlight the potential for enhanced treatment strategies against advanced squamous non-small cell lung cancer.